119 related articles for article (PubMed ID: 9973655)
1. Ebselen in acute middle cerebral artery occlusion: a placebo-controlled, double-blind clinical trial.
Ogawa A; Yoshimoto T; Kikuchi H; Sano K; Saito I; Yamaguchi T; Yasuhara H
Cerebrovasc Dis; 1999; 9(2):112-8. PubMed ID: 9973655
[TBL] [Abstract][Full Text] [Related]
2. Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial. Ebselen Study Group.
Yamaguchi T; Sano K; Takakura K; Saito I; Shinohara Y; Asano T; Yasuhara H
Stroke; 1998 Jan; 29(1):12-7. PubMed ID: 9445321
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotective effect of an antioxidant, ebselen, in patients with delayed neurological deficits after aneurysmal subarachnoid hemorrhage.
Saito I; Asano T; Sano K; Takakura K; Abe H; Yoshimoto T; Kikuchi H; Ohta T; Ishibashi S
Neurosurgery; 1998 Feb; 42(2):269-77; discussion 277-8. PubMed ID: 9482177
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotective efficacy of ebselen, an anti-oxidant with anti-inflammatory actions, in a rodent model of permanent middle cerebral artery occlusion.
Takasago T; Peters EE; Graham DI; Masayasu H; Macrae IM
Br J Pharmacol; 1997 Nov; 122(6):1251-6. PubMed ID: 9401794
[TBL] [Abstract][Full Text] [Related]
5. Ebselen: prospective therapy for cerebral ischaemia.
Parnham M; Sies H
Expert Opin Investig Drugs; 2000 Mar; 9(3):607-19. PubMed ID: 11060699
[TBL] [Abstract][Full Text] [Related]
6. Ebselen, a seleno-organic antioxidant, is neuroprotective after embolic strokes in rabbits: synergism with low-dose tissue plasminogen activator.
Lapchak PA; Zivin JA
Stroke; 2003 Aug; 34(8):2013-8. PubMed ID: 12855833
[TBL] [Abstract][Full Text] [Related]
7. Ebselen reduces autophagic activation and cell death in the ipsilateral thalamus following focal cerebral infarction.
Li Y; Zhang J; Chen L; Xing S; Li J; Zhang Y; Li C; Pei Z; Zeng J
Neurosci Lett; 2015 Jul; 600():206-12. PubMed ID: 26091880
[TBL] [Abstract][Full Text] [Related]
8. Oral pretreatment with ebselen enhances heat shock protein 72 expression and reduces myocardial infarct size.
Baljinnyam E; Hasebe N; Morihira M; Sumitomo K; Matsusaka T; Fujino T; Fukuzawa J; Ushikubi F; Kikuchi K
Hypertens Res; 2006 Nov; 29(11):905-13. PubMed ID: 17345791
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial.
Albers GW; von Kummer R; Truelsen T; Jensen JK; Ravn GM; Grønning BA; Chabriat H; Chang KC; Davalos AE; Ford GA; Grotta J; Kaste M; Schwamm LH; Shuaib A;
Lancet Neurol; 2015 Jun; 14(6):575-84. PubMed ID: 25937443
[TBL] [Abstract][Full Text] [Related]
10. Single-dose ebselen does not afford sustained neuroprotection to rats subjected to severe focal cerebral ischemia.
Salom JB; Pérez-Asensio FJ; Burguete MC; Marín N; Pitarch C; Torregrosa G; Romero FJ; Alborch E
Eur J Pharmacol; 2004 Jul; 495(1):55-62. PubMed ID: 15219820
[TBL] [Abstract][Full Text] [Related]
11. Protective effect of ebselen on experimental testicular torsion and detorsion injury.
Rifaioglu MM; Motor S; Davarci I; Tuzcu K; Sefil F; Davarci M; Nacar A
Andrologia; 2014 Dec; 46(10):1134-40. PubMed ID: 25388506
[TBL] [Abstract][Full Text] [Related]
12. Protective effects of ebselen on sodium-selenite-induced experimental cataract in rats.
Aydemir O; Güler M; Kaya MK; Deniz N; Üstündağ B
J Cataract Refract Surg; 2012 Dec; 38(12):2160-6. PubMed ID: 22999516
[TBL] [Abstract][Full Text] [Related]
13. Late-intervention study with ebselen in an experimental model of type 1 diabetic nephropathy.
Tan SM; Sharma A; Stefanovic N; de Haan JB
Free Radic Res; 2015 Mar; 49(3):219-27. PubMed ID: 25465090
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotective effects of ebselen in traumatic brain injury model: involvement of nitric oxide and p38 mitogen-activated protein kinase signalling pathway.
Wei L; Zhang Y; Yang C; Wang Q; Zhuang Z; Sun Z
Clin Exp Pharmacol Physiol; 2014 Feb; 41(2):134-8. PubMed ID: 24131109
[TBL] [Abstract][Full Text] [Related]
15. Ebselen decreases ozone-induced pulmonary inflammation in rats.
Ishii Y; Hashimoto K; Hirano K; Morishima Y; Mochizuki M; Masuyama K; Nomura A; Sakamoto T; Uchida Y; Sagai M; Sekizawa K
Lung; 2000; 178(4):225-34. PubMed ID: 10960557
[TBL] [Abstract][Full Text] [Related]
16. Ebselen attenuates cadmium-induced testicular damage in mice.
Ardais AP; Santos FW; Nogueira CW
J Appl Toxicol; 2008 Apr; 28(3):322-8. PubMed ID: 17624921
[TBL] [Abstract][Full Text] [Related]
17. Erdosteine and ebselen as useful agents in intestinal ischemia/reperfusion injury.
Tunc T; Uysal B; Atabek C; Kesik V; Caliskan B; Oztas E; Ersoz N; Oter S; Guven A
J Surg Res; 2009 Aug; 155(2):210-6. PubMed ID: 19505699
[TBL] [Abstract][Full Text] [Related]
18. Infarct pattern and clinical outcome in acute ischemic stroke following middle cerebral artery occlusion.
Lee KJ; Jung KH; Byun JI; Kim JM; Roh JK
Cerebrovasc Dis; 2014; 38(1):31-8. PubMed ID: 25196965
[TBL] [Abstract][Full Text] [Related]
19. Ebselen decreases oxygen free radical production and iron concentrations in the hearts of chronically iron-overloaded mice.
Davis MT; Bartfay WJ
Biol Res Nurs; 2004 Jul; 6(1):37-45. PubMed ID: 15186706
[TBL] [Abstract][Full Text] [Related]
20. Ebselen attenuates oxidative DNA damage and enhances its repair activity in the thalamus after focal cortical infarction in hypertensive rats.
He M; Xing S; Yang B; Zhao L; Hua H; Liang Z; Zhou W; Zeng J; Pei Z
Brain Res; 2007 Nov; 1181():83-92. PubMed ID: 17920569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
